Cardiol Therapeutics (TSE:CRDL) Shares Down 17.2% - Here's What Happened

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) shares were down 17.2% during mid-day trading on Monday . The company traded as low as C$1.24 and last traded at C$1.25. Approximately 480,129 shares changed hands during mid-day trading, an increase of 342% from the average daily volume of 108,711 shares. The stock had previously closed at C$1.51.Get Cardiol Therapeutics alerts:Cardiol Therapeutics Price PerformanceThe company has a market capitalization of C$129.00 million, a P/E ratio of -3.15 and a beta of 1.31. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The firm's 50-day moving average is C$1.50 and its 200-day moving average is C$1.65. Cardiol Therapeutics (TSE:CRDL - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. Analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year. About Cardiol Therapeutics (Get Free Report)Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.Further ReadingFive stocks we like better than Cardiol TherapeuticsHow to Invest in Small Cap Stocks Go on a Shopping Spree With 3 Top Retail ETFsStocks with Unusual Volume: How to Find Unusual Volume Stocks in Real TimeIf D-Wave Is Too Risky, Consider These 3 Quantum ETFs for DiversificationHow to Choose Top Rated StocksNVIDIA’s 13F Reveals 2 Q3 Winners—And 1 Painful MissThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Cardiol Therapeutics Right Now?Before you consider Cardiol Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here